Dynorphin A

Overview

Dynorphin A (Dyn A) is a heptadecapeptide (17 amino acids) belonging to the dynorphin family of endogenous opioid peptides. Identified in 1979 by Goldstein and colleagues from porcine pituitary extracts, dynorphin A possesses the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln, with an N-terminal tyrosine residue essential for opioid receptor activation. Dynorphin A exhibits the highest selectivity for the kappa-opioid receptor (KOR) among endogenous opioids.

Precursor and Biosynthesis

Dynorphin A is processed from prodynorphin (preprodynorphin), a large precursor that also yields dynorphin B, alpha-neoendorphin, and leucine-enkephalin. Prodynorphin is most densely expressed in the hypothalamus, hippocampus, spinal cord dorsal horn, and nucleus accumbens. Tissue-specific processing by prohormone convertases generates distinct dynorphin peptides depending on the enzymatic milieu present in each neuronal population.

Receptor Pharmacology and Signaling

Dynorphin A binds to the kappa-opioid receptor with an IC50 of approximately 0.5 nM in guinea pig brain homogenate binding assays. KOR activation by dynorphin A couples to Gi/Go proteins, inhibiting adenylyl cyclase and activating G protein-coupled inwardly rectifying potassium (GIRK) channels. Unlike mu-receptor activation, dynorphin A-mediated KOR signaling produces antinociception without euphoria.

Antinociceptive Properties

Intrathecal administration of dynorphin A produces potent antinociception in thermal and mechanical nociceptive assays, with efficacy approaching that of morphine. However, dynorphin A also exhibits non-opioid excitatory effects at high concentrations, including motor stimulation and allodynia mediated through NMDA receptor activation. This dual pharmacology complicates its therapeutic development.

Dysphoric Effects and Addiction

Central dynorphin A signaling contributes to dysphoria and aversion through KOR activation in limbic circuits. Elevated dynorphin expression in the nucleus accumbens during chronic stress and drug withdrawal produces aversive states that promote compulsive drug seeking. KOR antagonists have shown promise as potential anti-addiction therapeutics by blocking dynorphin-mediated dysphoria.

Neuroimmune Functions

Dynorphin A modulates inflammatory responses through KOR-dependent suppression of cytokine release from macrophages and microglia. This immunomodulatory role may be relevant in neuroinflammatory conditions where dynorphin levels are elevated in response to tissue injury.

References

1. Goldstein, A., et al. (1979). Dynorphin: a potent endogenous opioid peptide. Science, 204(4400), 1331-1333.
2. Chavkin, C., & Goldstein, A. (1981). Specific receptor for the opioid peptide dynorphin. Nature, 291(5810), 59-62.
3. Bruchas, M.R., et al. (2010). The dynorphin/KOR system as a target for treating mood disorders. Annual Review of Pharmacology and Toxicology, 50, 313-334.